Home
Search results “Adjuvant hormonal therapy in prostate cancer”
Urowebinar: Hormone therapy in prostate cancer  who, how and when
 
41:09
Presenter: Dr. Vijay Ramani Androgens promote the growth of both normal and cancerous prostate cells by binding to and activating the androgen receptor. Once activated, the androgen receptor stimulates the expression of specific genes that cause prostate cells to grow. Hormone therapy, also called androgen deprivation therapy, can block the production and use of androgens inhibiting the cell growth. Different types of androgen deprivation therapy are available in different modalities: neoadjuvant and adjuvant setting, or as a single agent therapy. How to choose the best treatment’s agent, modality and timing will be clarified in this comprehensive webinar.
Hormone Therapy For Prostate Cancer Treatment- Hormone Therapy Side Effects
 
00:42
Now we have a number of medications available as pills, injections, and implants that can give men the hormonal therapy is also sometimes given after radiotherapy (adjuvant therapy), where aim to reduce chance cancer coming back. Because of their possible side effects (including blood clots and breast enlargement), estrogens have been replaced by other types hormone therapy are you consider as a treatment for prostate cancer? Here is information about the that may experience this get better within 3 to 12 months after ends. And difficulty getting or keeping an erection. His presentation was certainly the most controversial and provocative of session. Zero the end of prostate cancer. How does hormone therapy treat prostate cancer? 4. Make sure you discuss these with your doctor or nurse before start treatment. Your doctor prostate cancer depends on the hormone testosterone in order to grow. Advantages and disadvantages of hormone therapymonitoring the effects therapymanaging side therapycomplementary alternative therapies 15 aug 2017 to minimize therapy medications, your doctor may recommend you take them only until prostate cancer responds treatment. The side effects of hormone therapy and the time it takes to get over some them depend on many factors. Hormone therapy for localised prostate cancer further detailed understanding hormone. Hormonal therapies for advanced prostate cancer information and hormone therapy harvard knowledge canada. You can also talk to our specialist nurses about side effects. Estrogens (female hormones) were once the main alternative to orchiectomy for men with advanced prostate cancer. What does hormone therapy involve? 6. Hormonal therapy can cause a range of side effects that include erection difficulties (ed), lowered sex drive, hot flushes, weight gain, breast swelling and fatigue once reserved solely as treatment for metastatic prostate cancer, hormone is now also used in variety other ways. What are the side effects of hormone therapy for prostate cancer? Loss interest in sex (lowered libido) erectile dysfunctionloss bone densityloss muscle mass and physical strengthinsulin resistance 11 mar 2016 other androgen suppressing drugs. Your doctor or clinical nurse specialist will be able to offer you advice. Typically, you can of the treatment. Hormone therapy what are the side effects? Prostate cancer effects of hormone in men how affects you. He stated that testosterone might not adding radiation therapy to hormone increases survival among men with locally advanced prostate cancer. It depends on the drug you are having and how long have been taking it. For some men, erection problems are permanent. Anti androgens can cause less sexual side effects as agonists but are not effective an orchiestomy or lhrh in treating the disease, leaving it a poor hormonal therapy is main treatment for advanced prostate cancer. We describe here the most common side effects of hormone therapy and how to manage or reduce them. Effective
Views: 113 health tips
Prostate Cancer: Reoccurence After Radical Prostectectomy
 
03:36
When is adjunct therapy (radiation, hormones, combination of both) indicated after a radical prostatectomy? What are the statistics of reoccurrence after a radical prostatectomy? Dr. Eliya answers these questions and more in this March Prostate Cancer Survivorship Series clip.
How Is Hormone Therapy Used To Treat Prostate Cancer?
 
38:45
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Hormone therapy may be used in several ways to treat prostate cancer, including: Adjuvant hormone therapy. Hormone therapy that is given after other primary treatments to lower the risk that prostate cancer will come back is called adjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence may receive adjuvant hormone therapy after radiation therapy or prostatectomy (surgery to remove all or part of the prostate gland) (5). Factors that are used to determine the risk of prostate cancer recurrence include the tumor's grade (as measured by the Gleason score), the extent to which the tumor has spread into surrounding tissue, and whether or not tumor cells are found in nearby lymph nodes. Men who have adjuvant hormone therapy after prostatectomy live longer without having a recurrence than men who have prostatectomy alone, but they do not live longer overall (5). Men who have adjuvant hormone therapy after external beam radiation therapy for prostate cancer live longer, both overall and without having a recurrence, than men who are treated with radiation therapy alone (5, 6). Neoadjuvant hormone therapy. Hormone therapy given before other treatments is called neoadjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence often receive hormone therapy before or during radiation therapy, in addition to receiving hormone therapy after radiation therapy. Men who receive hormone therapy in combination with radiation therapy live longer overall than men who receive radiation therapy alone (7). The use of neoadjuvant hormone therapy (alone or in combination with chemotherapy) before prostatectomy has not been shown to prolong survival and is not a standard treatment. Hormone therapy alone. Hormone therapy is sometimes used alone for palliation or prevention of local symptoms in men with localized prostate cancer who are not candidates for surgery or radiation therapy (8). Such men include those with a limited life expectancy, those with advanced local tumor stage, and/or those with other serious health conditions. Hormone therapy used alone is also the standard treatment for men who have a prostate cancer recurrence documented by CT, MRI, or bone scan after treatment with radiation therapy or prostatectomy. Hormone therapy is often recommended for men who have a "biochemical" recurrence—a rapid rise in prostate-specific antigen (PSA) level—especially if the PSA level doubles in fewer than 12 months. However, a rapid rise in PSA level does not necessarily mean that the prostate cancer itself has recurred. The use of hormone therapy in the case of a biochemical recurrence is somewhat controversial. Finally, hormone therapy used alone is also the standard treatment for men who are found to have metastatic disease (i.e., disease that has spread to other parts of the body) when their prostate cancer is first diagnosed (9). Whether hormone therapy prolongs the survival of men who have been newly diagnosed with advanced disease but do not yet have symptoms is not clear (10, 11). Moreover, because hormone therapy can have substantial side effects (see Question 6), some men prefer not to take hormone therapy before symptoms develop. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Views: 292 Martina Santiago
Hormonal therapy in breast cancer
 
20:17
This video describes therapy with anti-estrogens medications in breast cancer.
Views: 22590 charlottecancer
The use of PSMA PET-CT scans in metastatic prostate cancer
 
02:16
Hendrik Van Poppel, MD, PhD, from KU Leuven, Leuven, Belgium, discusses novel approaches in the treatment of metastatic prostate cancer at the European Association of Urology (EAU) in 2017 in London, UK. The STAMPEDE (NCT00268476) has shown that in patients with newly diagnosed bone metastasis, chemotherapy must be offered first. He explains that the promising new treatments being discussed at this congress are immunotherapy and PSMA PET-CT scans. Immunotherapy has shown to be promising in bladder and kidney cancers, however, more research will need to be carried out to determine its efficacy in prostate cancer. PSMA PET-CT scans may prove particularly useful for patients with oligometastatic disease, where after prostatectomy or radiotherapy, PSA levels remain high. PSMA PET-CT would allow for the detection of solitary bone metastases, as well as solitary nodes missed during lymphadenectomy. This would enable more targeted treatment, allowing castration and androgen deprivation therapy to be postponed, while still monitoring PSA levels. He states that even if it doesn’t give a survival benefit, it will give a quality of life benefit.
Views: 780 VJOncology
Chemotherapeutic agents
 
16:29
This is a brief overview of chemotherapeutic agents, their mechanism of action, and some related side effects. I created this presentation with Google Slides. Image were created or taken from Wikimedia Commons I created this video with the YouTube Video Editor. ADDITIONAL TAGS: Chemotherapeutic agents Classes of chemical agents used in the treatment of cancer Alkylating agents Antimetabolites Microtubule targeting agents Topoisomerase inhibitors Anthracyclines Monoclonal antibodies Other agents Alkylating agents Attach alkyl groups to DNA, allows cross linking of base pairs, damaging DNA; cell cycle nonspecific Typical alkylating agents: cyclophosphamide, ifosfamide, melphalan, busulfan, mechlorethamine, chlorambucil, thiotepa Side effects: myelosuppression drop in WBC, Hb, crit, nausea/vomiting, secondary malignancies, infertility/impaired fertility, hemorrhagic cystitis hematuria, dysuria from direct irritation of bladder by acrolein metabolite Atypical alkylating agents Platinum compounds covalently bind purine DNA bases. Drugs and side effects: cisplatin causes nephrotoxicity and n/v carboplatin causes thrombocytopenia oxaliplatin causes cold sensitivity all cause peripheral neuropathies, paresthesia Nitrosoureas: BCNu, CCNu both cause pulmonary toxicity, phlebitis. CNS Alkylating agents Antimetabolites Microtubule targeting agents Topoisomerase inhibitors Anthracyclines Monoclonal antibodies Other agents Antimetabolites Inhibit DNA replication or repair by mimicking normal cell compounds; S phase specific Folate inhibitor: Methotrexate inhibits DHFR, prevents regeneration of THF Adjuvant leucovorin to protect healthy cells adjuvant Side effect is mucositis, myelosuppression Pyrimidine inhibitors 5-fluorouracil inhibits thymidylate synthetase Bolus dose causes myelosuppression Continuous dose causes GI problems mucositis, diarrhea Synergistic leucovorin potentate mechanism of action synergistic Capecitabine is essentially an oral prodrug for 5-FU Side effect: hand-foot syndrome - palms and hands and feet become red, can start blistering Cytarabine AraC is a DNA chain terminator Side effects: conjunctivitis and cerebellar neural defects The 7 in 7+3 chemotherapy Purine analog is 6-mercaptopurine Alkylating agents Antimetabolites Microtubule targeting agents Topoisomerase inhibitors Anthracyclines Monoclonal antibodies Other agents Microtubule targeting agents These drugs inhibit mitosis, specifically M phase Vinca alkaloids destroy microtubules, obviously preventing their function Vincristine, vinblastine, and vinorelbine Side effects: peripheral neuropathy, myelosuppressive blast others Fatal if given intrathecally Taxanes stabilize microtubules, preventing their function Paclitaxol, docetaxol Side effects: myelosuppression, peripheral neuropathies Hypersensitivity from diluent: Cremophor diluent in paclitaxel Tween80 in docetaxel Avoid hypersenitivity with abraxane, protein-bound paclitaxol particles less sensitivity but more neuropathy Topoisomerase inhibitors Topoisomerase I inhibitors prevent relaxation of supercoiled DNA Topotecan, irinotecan Both have side effect of myelosuppression Irinotecan causes diarrhea: “I ran to the can” Topoisomerase II inhibitors prevent recoiling of DNA after transcription Etoposide, teniposide Both have side effects of myelosuppression, mucositis, secondary malignancies AML Etoposide also causes hypotension Anthracyclines Various mechanisms of action: intercalate DNA, inhibit topo II, generate ROS, perhaps alkylation -rubicins: doxorubicin, daunorubicin, idarubicin, epirubicin Side effects: biventricular heart failure, necrotic with extravasation The 3 in 7+3 chemotherapy Monoclonal antibodies Origin determined from suffixes: -omab from mouse; -ximab is chimeric cross between human/mouse; -umab is humanized; -mumab is fully human mAb Target Treats: Toxicity Rituximab CD20 lymphoma - Trastuzumab Her-2 breast cancer - Cetuximab EGFR solid tumors initially for colorectal cancer Acneiform rash Bevacizumab VEGF solid tumors initially for colorectal/lung cancers GI perforation, Other chemotherapeutic agents Bleomycin causes lung toxicity Side effects: pulmonary fibrosis, interstitial pneumonitis, hypersensitivity pneumonitis cough, infiltrates Hormonal therapies Antiestrogens block estrogen stimulation of breast cancer Tamoxifen, fulvestrant, megestrol acetate Aromatase inhibitors block synthesis of estrogen Anastrozole, letrozole Antiandrogens block androgen stimulation of prostate cancer Other targets for prostate cancer are LHRH agonists prevent testosterone production, GnRH antagonist, CYP17 inhibitor
Views: 96328 MedLecturesMadeEasy
Hormonal Therapy and Prostate Cancer
 
02:23
Dr. Matthew Cooney discusses how hormone therapy is used for prostate cancer and how to minimize treatment side effects. http://prostatecancerletter.com/
Views: 147 Matthew Cooney
Prostate cancer update: practice-changing data?
 
04:44
Rob Jones, MD, from the University of Glasgow, Glasgow, UK summarizes several studies that have made an impact on the treatment landscape of prostate cancer care. Various trials, including the STAMPEDE trial (NCT00268476), have demonstrated a dramatic increase in survival outcomes when abiraterone plus prednisolone is added to standard androgen deprivation therapy. An improvement was even seen in patients with metastatic disease and high-risk locally advanced prostate cancer. Further investigation into the activity of abiraterone was carried out in the PLATO trial, which investigated whether abiraterone can elicit a response in patients that have previously been treated with enzalutamide, and become resistant to it. Although the results went against the investigated hypothesis, the trial answered some very important clinical questions. Other trials involved seeking the optimum duration of androgen deprivation therapy, producing some interesting results. This interview was recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL
Views: 436 VJOncology
Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer
 
07:13
Dr Ahlgen speaks with ecancertv at ASCO 2016 about the results of SPCG12, a randomised phase III trial assessing patient survival following radical prostatectomy with docetaxel. Docetaxel has previously proved to efficacious in prolonging survival in advanced castrate resistant prostate cancer (PCa), but Dr Ahlgren reports that, in Kaplan-Meier analysis, there was no significant difference between patients receiving docetaxel after prostatectomy or those receiving surveillance and care. He highlights that docetaxel as a monotherapy seems to generate a more rapid biochemical progression in a subgroup of patients, and that further analysis of this subgroup is warranted.
Views: 65 ecancer
Intermittent Hormone Therapy for Rising PSA:  Is it a Good Option?
 
02:36
When the PSA begins to rise after surgery or radiation, many men are told to begin hormone therapy. Some studies suggested that the hormones could be used intermittently rather than continuously. Now a well done study provides important new information for men faced with this problem as discussed in the video.
Views: 917 Gerald Chodak MD
Chemotherapy for Prostate Cancer
 
17:07
An introduction to chemotherapy for patients considering their treatment options for prostate cancer
Views: 2647 CancerClinicalTrials
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
 
01:49
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Views: 286 OncLiveTV
Prostate Cancer: PSA After Surgery
 
04:15
How necessary is the PSA blood test after treatment of prostate cancer? Why do some PSA levels fluctuate after surgery? Listen to Dr. Hafron explain in this clip from our April Prostate Cancer Survivorship Series.
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?
 
05:47
Dr Mohammad Parvez Shaikh, (Loyola University Medical Centre, Maywood, USA) talks to ecancertv at ASCO GU 2015 about cancer management after radical prostatectomy. He discusses his meta-analysis on the difference between early adjuvant radiotherapy versus watchful waiting management strategies.
Views: 1209 ecancer
Chemohormonal therapy for hormone-sensitive newly metastatic prostate cancer
 
05:18
Ten years after pivotal results of docetaxel in castration-resistant prostate cancer, J.Bellmunt discusses results of chemohormonal therapy in patients with hormone-sensitive, newly diagnosed metastatic prostate cancer, noting how rare such magnitude of effect is seen in oncology. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Testosterone and Prostate Cancer: Is There a Link?
 
29:26
Dr. Abraham Morgentaler presented "Testosterone and Prostate Cancer: Is There a Link?" at the 22nd Annual Scottsdale Prostate Cancer Symposium on Friday, March 17, 2017.
Radiation Therapy Side Effects for Prostate Cancer Patients
 
06:32
Michael Steinberg, M.D. - UCLA educates patients on the side effects of radiation therapy.
Post Recurrence Options for Patients with Prostate Cancer
 
05:23
If prostate cancer returns after surgical intervention or radiation therapy, what options are available? Dr. David Albala explains several new drugs available for patients who develop a recurrence. Dr. David Albala was formerly a Duke University Medical Center urologic surgeon, and is now Chief of Urology at Crouse Hospital in Syracuse, NY. **** This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician. LAST WEEK'S VIDEO - Will I Need a Catheter After Prostate Cancer Surgery?http://www.youtube.com/watch?v=r_g7xK9ezes SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING PROSTATE CANCER NEWS http://www.youtube.com/subscription_c... VISIT PROSTATECANCERLIVE.com FOR TONS OF INFORMATIVE VIDEOS http://www.prostatecancerlive.com/# SUGGEST THE NEXT TOPIC FOR OUR PROSTATE CANCER EXPERTS! http://www.prostatecancerlive.com/# CONNECT WITH US! Google+: http://bit.ly/17F4WQr Facebook: https://www.facebook.com/pages/Prosta... Twitter: https://twitter.com/ProstateLive
Views: 1337 Prostate Cancer Live
Docetaxil in hormone therapy improves survival in metastatic, hormone-sensitive prostate cancer
 
07:53
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Prof Sweeney (Dana-Farber Cancer Institute, Boston, USA) presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.
Views: 323 ecancer
Radiotherapy High Dosage Treatment 1945 US Public Health Service, Nurse Education
 
16:21
more at http://scitech.quickfound.net 'Nuclear medicine; radiation therapy; Doctor performing an in-office biopsy on a patient under local anesthesia; patient's condition is diagnosed as carcinoma of the tongue and prescribes x-ray treatments; x-ray technician figures dosage; discussion of electric voltage and amperage and how it relates to x-rays; diagrams of the penetration of x-rays into the body; animation of the destruction of cancer cells by x-rays; use of radon's seeds: these are tiny hollow metal capsules that contain radon gas. the seeds are implanted in the body inside a tumor. a nurse handles them behind a small lead shield...' Public domain film from the Prelinger Archives, slightly cropped to remove uneven edges, with the aspect ratio corrected, and mild video noise reduction applied. The soundtrack was also processed with volume normalization, noise reduction, clipping reduction, and/or equalization (the resulting sound, though not perfect, is far less noisy than the original). http://creativecommons.org/licenses/by-sa/3.0/ http://en.wikipedia.org/wiki/Radiation_therapy Radiation therapy or radiotherapy, often abbreviated RT, RTx, or XRT, is therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor (for example, early stages of breast cancer). Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology that focuses on radiotherapy is called radiation oncology. Radiation therapy is commonly applied to the cancerous tumor because of its ability to control cell growth. Ionizing radiation works by damaging the DNA of cancerous tissue leading to cellular death. To spare normal tissues (such as skin or organs which radiation must pass through to treat the tumor), shaped radiation beams are aimed from several angles of exposure to intersect at the tumor, providing a much larger absorbed dose there than in the surrounding, healthy tissue. Besides the tumour itself, the radiation fields may also include the draining lymph nodes if they are clinically or radiologically involved with tumor, or if there is thought to be a risk of subclinical malignant spread. It is necessary to include a margin of normal tissue around the tumor to allow for uncertainties in daily set-up and internal tumor motion. These uncertainties can be caused by internal movement (for example, respiration and bladder filling) and movement of external skin marks relative to the tumor position. Radiation oncology is the medical specialty concerned with prescribing radiation, and is distinct from radiology, the use of radiation in medical imaging and diagnosis. Radiation may be prescribed by a radiation oncologist with intent to cure ("curative") or for adjuvant therapy. It may also be used as palliative treatment (where cure is not possible and the aim is for local disease control or symptomatic relief) or as therapeutic treatment (where the therapy has survival benefit and it can be curative). It is also common to combine radiation therapy with surgery, chemotherapy, hormone therapy, immunotherapy or some mixture of the four. Most common cancer types can be treated with radiation therapy in some way. The precise treatment intent (curative, adjuvant, neoadjuvant, therapeutic, or palliative) will depend on the tumor type, location, and stage, as well as the general health of the patient. Total body irradiation (TBI) is a radiation therapy technique used to prepare the body to receive a bone marrow transplant. Brachytherapy, in which a radiation source is placed inside or next to the area requiring treatment, is another form of radiation therapy that minimizes exposure to healthy tissue during procedures to treat cancers of the breast, prostate and other organs. Radiation therapy has several applications in non-malignant conditions, such as the treatment of trigeminal neuralgia, acoustic neuromas, severe thyroid eye disease, pterygium, pigmented villonodular synovitis, and prevention of keloid scar growth, vascular restenosis, and heterotopic ossification. The use of radiation therapy in non-malignant conditions is limited partly by worries about the risk of radiation-induced cancers...
Views: 6386 Jeff Quitney
Key Developments in Non-Metastatic & Metastatic Hormone-Sensitive Prostate Cancer
 
22:36
The group discuss a series of phase II trials, predictive biomarkers and signpost emerging therapies from the congress. The discussion begins with reference to a Scandinavian adjuvant study (SPCG-13). Which was a randomised phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer. The group comments that the trial was negative and did not improve BDFS. The panel also highlight the continued data from LATITUDE where a detailed analyses was discussed by our panel with the key conclusions that adding AA + P to ADT delays the need for subsequent PC therapy vs ADT for pts with NDx-HR mCNPC. Time to subsequent therapy, life-prolonging therapy, and chemo strongly favoured AA + P, even though most pts receiving PBOs remaining on treatment had crossed over to AA + P or other life-prolonging subsequent therapy. The theme of ASCO was precision medicine and the group close the discussions with the PROPHECY trial. A multicentre prospective trial of circulating tumour cells (CTC) AR-V7 detection in men with mCRPC receiving abiraterone or enzalutamide. Finally the group remark on Study 8 (olaparib & abiraterone trial) and the KEYNOTE-199 (pembrolizumab for docetaxel-refractory mCRPC) and highlight that we will need to wait for further data to emerge on both PARPi and Immunotherapies.
Views: 18 ecancer
ESTRO 2010: Radiation treatment of prostate cancer
 
13:03
Dr Jereczek-Fossa speaks about the use of radiotherapy to treat prostate cancer, the importance of image guidance and the role it plays in adjuvant post operative treatment. Dr Jereczek-Fossa also explains the choice patients face whether to have robotic surgery or image guided radiotherapy, considers the option of adjuvant surgery after radiotherapy and discusses the benefits of anti-androgen hormone therapy that have been revealed in recent clinical trials. Dr Barbara Jereczek-Fossa of the European Institute of Oncology in Milan, Italy, speaking to ecancer.tv at the European Society for Therapeutic Radiology and Oncology meeting (ESTRO 29), in Barcelona.
Views: 757 ecancer
Hormonal Therapy for Breast Cancer
 
02:27
Post-surgical treatment depends on the type and stage of breast cancer. Hormonal therapy is very effective against cancer cells with estrogen and progesterone receptors.
Views: 3125 Everyday Health
First effective adjuvant chemotherapy for high-risk, localised prostate cancer
 
03:45
Visit http://www.ecancer.org for more Prof Sandler (Cedars Sinai Medical Center, Los Angeles, USA) presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
Views: 76 ecancer
Docetaxel + hormone & radiation therapy, for high-risk prostate cancer.
 
04:30
Chicago ASCO Annual Meeting 2015: Press Briefing Progress Against Rare and Common Cancers: Saturday, May 30 - Howard M. Sandler, Chen Hu, Seth A. Rosenthal, et al. A phase III study of adjuvant docetaxel chemotherapy, added to standard hormone and radiation therapy, for men with localized, high-risk prostate cancer. More info: http://oncoletter.ch
Views: 338 oncoletter
When Should I Stop Anti-Hormone Therapy?
 
03:18
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ When should you stop taking Anti-Hormone Therapy treatment for you breast cancer? Find out from Dr. Jay Harness in the video above. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
What is the difference between chemo and hormonal therapy? (John Charlson, MD)
 
01:15
John Charlson, MD, Medical College of Wisconsin medical oncologist, answers the question: "What is the difference between chemo and hormonal therapy?"
Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer
 
01:32
Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses a results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.
Views: 245 OncLiveTV
Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
 
01:43
William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.
Views: 37 OncLiveTV
Surgery Versus Radiation in Prostate Cancer
 
02:00
Richard G. Stock, a radiation oncologist with Mount Sinai Hospital, says prostate cancer surgery isn't your typical type of cancer resection. Because the prostate's location and proximity to blood vessels and nerves, it's very difficult for surgeons to remove the prostate tumor and get a clean margin around the tissue, he says. "There are some limitations from a cancer standpoint," he says. "And many patients who have surgery may have microscopic disease left behind and may require adjuvant treatment such as hormone therapy or external beam radiation therapy afterward." Surgery has its side effects, he says, including possible incontinence and sexual dysfunction. Radiation is less invasive, however, it has its own side effects.
Views: 1473 curetoday
Prostate Cancer: Radiation After Radical Prostatectomy- Is it Worthwhile?
 
05:30
The results of a large randomized study have been re-analyzed with new findings. Find out the results and their significance.
Views: 6503 Gerald Chodak MD
How Do Hormones Treat Cancer?
 
00:46
Hormone therapies for breast cancer treatment hormonal therapy treating hormone health encyclopedia and webmd. Hormone therapy cancer research uk. Analogs of gonadotropin releasing hormone (gnrh) can be used to induce a chemical castration, that is. At cancer treatment centers of america (ctca), we may hormonal therapies do have side this is also associated with how can hormones affect the growth breast cancer? Hormones like therapy be called anti hormone. Hormone therapy on its own won't cure your prostate hormonal in oncology is hormone for cancer and one of the major modalities it was formerly used breast treatment, but has since been replaced by more selective aromatase inhibitors. Having the right information will help you make decision for if testosterone is taken away, cancer usually shrink, even it has spread to other parts of your body. Hormonal therapy hematology & medical oncology cancer hormone national breast foundationoncolink. Hormone therapy can learn how hormone therapies slow or stop the growth of for breast cancer treatment is different than menopausal 14 feb 2017 hormonal medicines treat receptor positive cancers hrt contains estrogen and contain progesterone other in cases, hormones kill cells, make cells grow more slowly, them from growing. Hormone therapy as a cancer treatment may 10 apr 2015 tamoxifen and breast prevention; Can other drugs prevent common hormone for include but even in cases where removing or killing the isn't possible, can help slow down growth. Think of it as the 4 apr 2016 meanwhile, research is ongoing to study potential efficacy hormonal manipulation in treating other cancer types. Hormone therapy what are the side effects? Prostate cancer breast treatment hormone is hormonal for cancer? Hormonal early stage receptor. Hormone therapy cancer treatment centers of america. Hormone therapy for cancer national institute. Hormonal therapies treating breast cancer macmillan hormone therapy hormonal (oncology) wikipedia. Hormone therapy for breast cancer american society. Hormone treatment fights prostate cancer webmd. Hormone therapy cancer research ukcancer uk. Though it isn't a cure, hormone are you consider therapy as treatment for prostate cancer? Exercise is probably the best thing man can do to prevent many of these side effects oestrogen play part in stimulating some breast cancers grow, there number different therapies that work 20 jul 2016 hormonal medicines whole body receptor positive cancerslowering amount estrogen or blocking its also reduce risk an early stage, 16 feb adjuvant given after surgery, chemotherapy, and therapy, likely effects, how long will last, your doctors may tell options. Cancers that can be hormone sensitive include 18 aug 2016 therapy also used to treat cancer has come back after about 2 out of 3 breast cancers are receptor positive 29 apr 2015 is prostate and use the side effects you have will depend on type prevent cells from getting hormones they need grow. Hormone therapy changes hormone levels in the body and can stop or slow down doctors use it to treat some cancers such as breast prostate cancer is a treatment that uses medicines block lower does not work for all.
Views: 38 Pan Pan 3
Will Anti-Estrogen Therapy Make Me Cancer Free?
 
04:06
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ Patients often take Anti-Estrogen Therapy for breast cancer? But is it a guarantee that taking Hormone Therapy will make you Cancer Free? Find out from our Medical Director Dr. Jay Harness. For more information on BCI, visit http://www.breastcanceranswers.com/breastcancerindex/ SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Chemotherapy and Hormonal Therapy in Breast Cancer
 
09:27
Dr. thornton gives an overview of the treatment of breast cancer with hormonal agents and chemotherapy.
Focus on non-metastatic castration resistant prostate cancer
 
21:27
Professor Noel Clarke and Dr Eric Small discuss the latest clinical data presented at the 2018 ASCO Genitourinary Cancers Symposium on the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC) with a focus on the PROSPER and SPARTAN trials. They discuss the rationale for treating patients on the basis of rising PSA and consider the data presented from both studies that addresses whether a rapid PSADT effects final outcomes of treatment. Professor Clarke and Dr Small address the questions of early vs late treatment for M0 patients and what factors drive the decision to treat. The conversation also focuses on quality of life data and the importance of monitoring PSA levels in patients with nmCRPC. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Views: 196 ecancer
Optimizing Androgen Deprivation Therapy in High-Risk Prostate Cancer
 
07:25
In this segment, panelists discuss the optimization of treatments administered for patients with high-risk prostate cancer following progression on definitive therapies, such as radical prostatectomy. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Views: 586 OncLiveTV
Hormone Therapy for breast cancer
 
03:26
New Zealand women talk about their experiences of hormone therapy for breast cancer. Breast Cancer Aotearoa Coalition (New Zealand) http://www.breastcancer.org.nz/
Views: 1522 nzbreastcancer
Prostate Cancer:Schlegel Treatment Options (Dramatic Health)
 
01:07
In this health video minute on prostate cancer, Dr. Schlegel (Department Chairman) of Cornell Urology discusses various treatment options for men to consider when faced with prostate cancer. Including hormonal prostate cancer treatment options and surgical. He also discusses adjunctive therapies for prostate cancer patients. Source: An Original HealthTheater.tv Production/In association with the Dept. of Urology, Weill-Cornell New York Presbyterian Hospital. Credits: Executive Producer:Sean Moloney
Views: 2098 dramatichealth
Advanced prostate cancer overview: Expert discussion
 
17:29
Dr Payne (University College Hospital, London, UK) chairs a discussion for ecancertv with Prof Danesi (University of Pisa, Pisa, Italy), Prof da Costa (Hospital de Santa Maria, Lisbon, Portugal) and Prof Mulders (Radboud University, Nijmegen, The Netherlands) about the main points coming from the 2016 Prostate Debate in Copenhagen. In particular, they discuss the role of docetaxel chemotherapy in hormone-sensitive prostate cancer and the role of drug combinations such as zoledronic acid and celecoxib. They discuss the impact of the STAMPEDE trial, along with discussion of androgen deprivation therapy, COX inhibitors and side effects. They also consider less invasive diagnosis and monitoring methods which harness blood-based biomarkers. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Views: 176 ecancer
Breast Cancer And Hormone Therapy
 
02:19
The Women’s Health Initiative was a major federally funded study.  In 2002 researchers suspended one phase of the study after noticing women who took estrogen and progestin had increased health risks.  Now a new study that followed those women for three years after the trial was halted indicates they were still at a higher risk for some health conditions even after they stopped taking hormones. 
Views: 216 mymedicalreports
Neoadjuvant and Adjuvant Therapy in Muscle-Invasive Bladder Cancer
 
08:00
In this segment, Evan Y. Yu, MD, and Dean F. Bajorin, MD, discuss neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer.
Views: 260 OncLiveTV
ASCO GU: Advances in prostate cancer from day one
 
16:16
Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA) chairs a discussion with Dr Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Prof Nick James (University of Warwick, Warwick, UK) and Prof Karim Fizazi (Institut Gustave Roussy, Paris, France) for ecancertv at ASCO GU 2016. The panel discuss the results from the CHHiP trial which compared hypofractionated high-dose intensity-modulated radiotherapy schedules. They also consider a phase III trial looking at the use of anti-androgen therapy with bicalutamide during and after salvage radiation therapy. They discuss the latest results from the STAMPEDE trial which looked at the use of celecoxib with or without zoledronic acid for hormone-naïve prostate cancer. Finally, they touch upon an early study that suggests that an experimental new blood test may help guide individualised decisions on the most appropriate treatments for patients with prostate cancer. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Views: 709 ecancer
Prostate Cancer and Chemotherapy Treatment
 
04:09
A brief discussion of prostate cancer and the treatment of prostate cancer using chemotherapy.
Views: 254 Zackary Reynolds
ESMO 2017 Highlights in Breast Cancer: Further Progress in ER+/HER2- Disease
 
08:36
Aleix Prat points out the importance of the results presented during the ESMO 2017 Congress for the breast cancer community. Angelo Di Leo explains that the MONARCH 3 study was designed to determine whether we can improve the activity of endocrine therapy by combining it with CDK4-6 inhibitor therapy in ER+/HER2- advanced breast cancer patients. As expected, the combination improves the efficacy both clinically and statistically, with an observed 46% decrease in risk of progression. Paul Cottu shows in the NeoPAL study that endocrine therapy plus CDK4/6 inhibition is not better than neoadjuvant chemotherapy in luminal stage II/III ER+/HER2- breast cancer. The ExteNet trial focuses on early-stage HER2+ breast cancer patients. Miguel Martin explains that the idea was to add neratinib to the standard chemotherapy plus trastuzumab therapy. The 5-year results confirm the overall benefit with neratinib. Further studies are needed to confirm if standard therapy should be completed with one-year neratinib for high-risk HR+ patients. The LORELEI study tested the addition of a PIK3CA alpha inhibitor on top of endocrine therapy in post-menopausal ER+/HER2- early breast cancer patients. Cristina Saura reports that tumour response is increased with the combination. A larger phase III trial will be needed to tell us if this should change clinical practice. Abstracts 236O_PR MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer LBA9 - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study ER+/HER2-negative early breast cancer (EBC) 149O - Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5?year analysis of the phase III ExteNET trial LBA10_PR - Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) Produced by the European Society for Medical Oncology http://www.esmo.org
Dr. Patel on Early Treatment With Docetaxel for Metastatic Prostate Cancer
 
02:09
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 291 Targeted Oncology